GlycoMimetics is Drug Discovery in United States that focus on carbohydrate biology business. Founded in 2003. They cover business area such as GlycoMimetics Inc, development, novel glycomimetic drug, unmet medical need, disease, carbohydrate biology, a key role, molecule, important biological process, expertise, carbohydrate chemistry, knowledge, a pipeline, proprietary glycomimetic, inflammation, cancer, infection.
2003
( 21 years old in 2024 )
Carbohydrate Biology
-
401 Professional Drive
Suite 250
Gaithersburg, MD 20879
United States
Private
GlycoMimetics Incdevelopmentnovel glycomimetic drugunmet medical needdiseasecarbohydrate biologya key rolemoleculeimportant biological processexpertisecarbohydrate chemistryknowledgea pipelineproprietary glycomimeticinflammationcancerinfection
* We use standard office opening hours in near GlycoMimetics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
GlycoMimetics is Drug Discovery business from United States that founded in 2003 (21 years old in 2024), GlycoMimetics business is focusing on Carbohydrate Biology.
GlycoMimetics headquarter office and corporate office address is located in 401 Professional Drive Suite 250 Gaithersburg, MD 20879 United States.
GlycoMimetics was founded in United States.
In 2024, GlycoMimetics is currently focus on carbohydrate biology sector.
Above is snippet of Google Trends for "carbohydrate biology" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with GlycoMimetics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
